When a biotech company is preparing to launch a new therapy, the stakes couldn’t be higher. Every delay in reaching the right patients translates to lives that could have been changed sooner. That’s why ClearView Healthcare Partners, a leading life sciences consultancy, is partnering with Vi to transform how strategic insights turn into real-world execution.

In a recent conversation, Ryan Tubman — Partner at ClearView Healthcare and one of the leaders of the firm’s Data and Analytics practice — shared how combining ClearView’s strategic expertise with Vi’s Enterprise AI platform is changing what life sciences consulting can deliver.

The Challenge: Answering Hard Questions Quickly

ClearView’s mission is to help pharma, biotech, and medtech leaders bring new innovations to market. Every day, the firm’s teams are trusted to guide decisions that shape clinical strategies, market launches, commercial plans, and ultimately, patient outcomes.

But doing this well depends on two things: reliable information, and speed.

Where Traditional Approaches Fall Short

“Traditionally, consulting has meant digging through research, talking to experts, and building models using traditional medical and claims data,” Ryan explains. It’s a proven playbook — but it has limits. Claims data is often months behind real events. Manual analysis slows iteration. And disconnected research can leave gaps between insight and action.

In a landscape where every week matters — especially for therapies targeting life-threatening or rare conditions — those limits come with real costs.

The Vi + ClearView Partnership: Precision Meets Execution

This is where the partnership with Vi changes the equation. “The Vi plus ClearView partnership enables our clients to be precise, predictive, and actionable,” Ryan says, “with a clear line from data to strategy to execution.”

The Vi + ClearView partnership enables our clients to be precise, predictive, and actionable — with a clear line from data to strategy to execution.“

Ryan Tubman, Partner, ClearView Healthcare Partners

Rather than stopping at a set of recommendations in a slide deck, ClearView’s strategic guidance now flows directly into activation — powered by Vi’s Enterprise AI platform.

From Patient Profiles to Real-World Signals

Consider a common scenario: a biotech company preparing to launch a new therapy is wrestling with two critical questions. Which patients should we focus on first? And how do we make sure providers know where to direct them?

With Vi Activate, ClearView can identify the exact patient populations that fit a therapy’s profile — and go further by layering in behavioral signals such as how patients search for care, what services they’re already using, and the best channels to reach them.

The result is a dramatically sharper picture of who to engage and how to reach them, grounded in real-time data rather than lagging claims records.

Where It Matters Most: Rare Disease

Nowhere is this capability more valuable than in rare disease, an area where traditional approaches often struggle most.

Finding Patients Who Are Invisible in Claims Data

“Patient identification and targeting in these conditions is one of the most challenging tasks in biopharma,” Ryan notes, “because the populations are often small and invisible in claims data.”

Rare disease patients are frequently undiagnosed, misdiagnosed, or scattered across specialties that don’t immediately signal their condition. Conventional data sources can miss them entirely.

By combining broad health coverage with real-time intent signals, Vi and ClearView can uncover and connect these patients sooner — while equipping healthcare providers (HCPs) with the right information at the right moment.

Vi has been a game-changer for enrolling these patients into trials or getting them on therapy.“

Ryan Tubman

Faster Outreach, Better Access

The impact is twofold. First, trial enrollment and time-to-therapy accelerate, because the right patients surface earlier in the process. Second, and just as important, patients who might otherwise slip through the cracks gain access to treatments that can change their lives.

Strategy That Connects to Execution — With ROI to Prove It

What sets this partnership apart isn’t any single capability. It’s the way strategy flows directly into execution, with measurable results on the other end.

“ClearView is still delivering best-in-class life sciences and biopharma insights, services, and strategy,” Ryan emphasizes. “But with the Vi partnership, our recommendations don’t just stop there. With Vi, they connect directly to execution — with ROI we can prove.”

Our recommendations don’t just stop there. With Vi, they connect directly to execution — with ROI we can prove.“

Ryan Tubman

For clients, that means fewer handoffs between insight and action, faster time to impact, and a clearer business case for every initiative.

A New Standard for Life Sciences Consulting

The broader shift here is significant. Life sciences companies are under growing pressure to move faster, operate more efficiently, and demonstrate value at every step. Traditional consulting models — however rigorous — can no longer keep pace on their own.

By pairing deep strategic expertise with Enterprise AI that executes in real time, ClearView and Vi are setting a new bar for what life sciences consulting can deliver.

Together, we’re setting a new standard for life sciences consulting.“

Ryan Tubman

Key Takeaways

• Strategy meets execution. The Vi + ClearView partnership closes the gap between insight and action, turning strategic recommendations into real-world activation.
• Precision patient identification. Using behavioral signals and real-time intent data, teams can pinpoint the right patients and reach them through the right channels.
• A breakthrough for rare disease. By uncovering patients who are invisible in traditional claims data, Vi helps accelerate trial enrollment and therapy access.
• Provider enablement at the right moment. HCPs receive relevant information when it matters most, supporting better care decisions.
• Measurable ROI. Clients benefit from faster launches, lower costs, and provable returns on their investment.
• A new standard. Together, ClearView and Vi are redefining what modern life sciences consulting looks like — strategic, predictive, and directly tied to outcomes.

Ready to see what Enterprise AI can do for your biopharma strategy? Learn more about Vi for Biopharma →